# Piramal Pharma Limited (PPLPHARMA)

> PPLPHARMA closed at ₹238.91 on 30 Oct 2026, market cap ₹31,737 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Piramal Pharma Limited (NSE: PPLPHARMA) closed at ₹238.91 on 30 Oct 2026, +24.0% over one year, against a 52-week range of ₹132.30 – ₹240.00.

In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹2,617 cr and net profit of ₹6 cr, a 0.2% net margin; revenue grew 28.1% year on year.

No trailing P/E is published: trailing twelve-month earnings are negative (-209 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.

From the balance sheet dated 30 Sept 2026: return on equity 0.3%, ROCE 4.5%, debt-to-equity 0.70, Piotroski F-score 5 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 3% of 63 sector peers; PBT margin higher than 3% of 63 sector peers; ROE higher than 5% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹238.91 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | +14.8% / +44.4% / +24.0% |
| 52-week low – high | ₹132.30 – ₹240.00 |
| Market capitalisation | ₹31,737 cr |
| Price / book | 3.90 |
| EV / EBITDA | 30.8 |
| TTM EPS | ₹-1.57 |
| TTM net profit | ₹-209 cr |
| Quarter revenue | ₹2,617 cr |
| Quarter net profit | ₹6 cr |
| Net margin | 0.2% |
| Revenue growth (YoY) | +28.1% |
| Return on equity | 0.3% |
| ROCE | 4.5% |
| Debt / equity | 0.70 |
| Current ratio | 1.41 |
| Free cash flow | ₹-468 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹58.8 cr |

## Questions

### What were Piramal Pharma Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Piramal Pharma Limited reported revenue of ₹2,617 cr and net profit of ₹6 cr (consolidated), filed with the exchange on 27 Oct 2026.

### What is Piramal Pharma Limited's ROE?

Return on equity is 0.3% based on the balance sheet dated 30 Sept 2026.

### Does Piramal Pharma Limited have debt?

Debt-to-equity is 0.70 on the balance sheet dated 30 Sept 2026.

### What is PPLPHARMA's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, PPLPHARMA traded between ₹132.30 and ₹240.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/PPLPHARMA

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._